[go: up one dir, main page]

BR9815116A - Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna - Google Patents

Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna

Info

Publication number
BR9815116A
BR9815116A BR9815116-9A BR9815116A BR9815116A BR 9815116 A BR9815116 A BR 9815116A BR 9815116 A BR9815116 A BR 9815116A BR 9815116 A BR9815116 A BR 9815116A
Authority
BR
Brazil
Prior art keywords
treat
prostate cancer
conjugate
pharmaceutical composition
benign prostatic
Prior art date
Application number
BR9815116-9A
Other languages
English (en)
Inventor
Stephen F Brady
Dong-Mei Feng
Victor M Garsky
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9815116A publication Critical patent/BR9815116A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

"CONJUGADO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA TRATAR CâNCER DE PRóSTATA, E PARA TRATAR HIPERPLASIA PROSTáTICA BENIGNA". Conjugados químicos que incluem oligopeptídeos, que têm sequências de aminoácidos que são seletiva e proteoliticamente clivados por antígeno livre específico da próstata (PSA), e agentes citotóxicos conhecidos são apresentados. Os conjugados da invenção são caracterizados por ligação do oligopeptídeo clivável ao átomo de oxigênio na posição 4 em um medicamento de vinca que tenha sido desacetilada. Tais conjugados são úteis no tratamento do câncer prostático e da hipertrofia prostática benigna (BPH).
BR9815116-9A 1997-12-02 1998-11-25 Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna BR9815116A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer
PCT/US1998/025358 WO1999028345A1 (en) 1997-12-02 1998-11-25 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
BR9815116A true BR9815116A (pt) 2000-10-10

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815116-9A BR9815116A (pt) 1997-12-02 1998-11-25 Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna

Country Status (26)

Country Link
US (2) US20060148718A1 (pt)
EP (1) EP1036093A1 (pt)
JP (1) JP2001525337A (pt)
KR (1) KR100580137B1 (pt)
CN (1) CN1181092C (pt)
AR (1) AR016427A1 (pt)
AU (1) AU744652B2 (pt)
BG (1) BG65486B1 (pt)
BR (1) BR9815116A (pt)
CA (1) CA2311615A1 (pt)
DZ (1) DZ2665A1 (pt)
EA (1) EA002745B1 (pt)
EE (1) EE200000333A (pt)
HR (1) HRP20000367A2 (pt)
HU (1) HUP0100350A3 (pt)
ID (1) ID24735A (pt)
IL (1) IL136167A0 (pt)
IS (1) IS5502A (pt)
NO (1) NO20002804L (pt)
NZ (1) NZ504615A (pt)
PE (1) PE20000009A1 (pt)
PL (1) PL197006B1 (pt)
SK (1) SK8282000A3 (pt)
TR (1) TR200002260T2 (pt)
TW (1) TW577897B (pt)
WO (1) WO1999028345A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942128D1 (de) * 1998-12-11 2010-04-22 Coulter Pharm Inc Prodrugs und verfahren zu deren herstellung
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
NZ583931A (en) 2007-08-17 2012-06-29 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9371362B2 (en) * 2012-08-15 2016-06-21 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
EP2916835A4 (en) * 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
KR102575825B1 (ko) 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
CN105229742A (zh) 2013-04-30 2016-01-06 惠普发展公司，有限责任合伙企业 存储器访问速率
SG11201602249RA (en) 2013-10-18 2016-05-30 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA035171B1 (ru) 2013-11-14 2020-05-08 Эндосайт, Инк. Конъюгаты на основе связывающихся с psma лигандов или ингибиторов psma для позитронно-эмиссионной томографии
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
BR112020020961A2 (pt) 2018-04-17 2021-01-19 Endocyte, Inc. Métodos de tratamento de câncer
CN120097929A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
WO2022136586A1 (en) 2020-12-22 2022-06-30 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
GR81790B (pt) * 1983-04-29 1984-12-12 Omnichem Sa
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
EP0855910A4 (en) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugates that can be used to treat benign prostate hyperplasia
WO1998010651A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
TR200002260T2 (tr) 2000-12-21
NO20002804D0 (no) 2000-05-31
HUP0100350A2 (hu) 2001-08-28
PL340768A1 (en) 2001-02-26
US20060148718A1 (en) 2006-07-06
WO1999028345A1 (en) 1999-06-10
EE200000333A (et) 2001-08-15
JP2001525337A (ja) 2001-12-11
HRP20000367A2 (en) 2000-12-31
EP1036093A1 (en) 2000-09-20
DZ2665A1 (fr) 2003-03-22
NO20002804L (no) 2000-07-21
PL197006B1 (pl) 2008-02-29
HUP0100350A3 (en) 2001-09-28
ID24735A (id) 2000-08-03
CN1284086A (zh) 2001-02-14
IL136167A0 (en) 2001-05-20
CN1181092C (zh) 2004-12-22
SK8282000A3 (en) 2000-11-07
EA002745B1 (ru) 2002-08-29
NZ504615A (en) 2003-05-30
KR100580137B1 (ko) 2006-05-16
AR016427A1 (es) 2001-07-04
CA2311615A1 (en) 1999-06-10
BG65486B1 (bg) 2008-09-30
PE20000009A1 (es) 2000-01-27
IS5502A (is) 2000-05-19
TW577897B (en) 2004-03-01
US20070021350A1 (en) 2007-01-25
AU1612399A (en) 1999-06-16
BG104563A (en) 2001-04-30
EA200000603A1 (ru) 2000-12-25
AU744652B2 (en) 2002-02-28
KR20010032687A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
BR9815116A (pt) Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
EP1009420A4 (en) CONJUGATES WHICH ARE USEFUL IN TREATING PROSTATE CANCER
DK1075282T3 (da) PEG-LHRH-analog-konjugater
IL150692A0 (en) FACTOR VII OR VIIa-LIKE MOLECULES
BR0115953A (pt) Complexos de derivados de fosfato
HUP0100586A2 (hu) Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
TR199902703T2 (xx) Proteaz inhibit�rleri.
ATE283043T1 (de) Medikament zur behandlung intraepithelialer prostataneoplasie
Schneider et al. Dextramabs: a novel format of antibody‐drug conjugates featuring a multivalent polysaccharide scaffold
WO2004041828A1 (en) Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
IL163976A0 (en) Pharmaceutical combination for the treatment of benign prosttic hyperplasia or for the long-term prevention of acute urinary retention
DE69303919D1 (de) Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie
WO2001030804A3 (en) Salt form of a conjugate useful in the treatment of prostate cancer
WO2004089379A3 (en) Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug
YU34400A (sh) Konjugati korisni u lečenju kancera prostate
FR2812200B1 (fr) Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote ; et utilisations
ECSP982763A (es) Conjugados utiles en el tratamiento de cancer de prostata
BR9811875A (pt) Composição e processo de tratamento de câncer com ácido tânico e complexos de tanino
ECSP972297A (es) Conjugados utiles en el tratamiento de cancer de prostata
Li et al. Peptidyl Asparaginyl Ligase-Mediated Orthogonal Ligation at Non-Asx Peptide Bonds for d-Peptide Cyclization and Antibody Dual Labeling
DE69807166D1 (de) Prostata-spezifische Antigen Inhibitore

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: AS REIVINDICACOES 1 A 13 CARECEM DE ATIVIDADE INVENTIVA PERANTE OS DOCUMENTOS WO9600503, WO9712624E WO9714416; FACE AO ACIMA EXPOSTO, ENTENDE-SE QUE A MATERIA REQUERIDA NAO ATENDE AOS REQUISITOS DE PATENTEABILIDADE DE ACORDO COM OS ARTIGOS 8O C/C 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 5/103 (2006.01), A61K 47/65 (2017.0